TXG Drops 17% as Analyst Targets Overtaken by Reality

Short positioning is elevated but not tightening rapidly. Short interest runs at 14.6% of the free float, near its 30-day range, up just 0.5% on the week. The borrow market is loose. Availability is at 345%, meaning roughly three and a half shares are available to lend for every one already out on loan. Cost to borrow is 0.53%, barely moved from a month ago. That combination, heavy short interest with ample available supply, means there is no mechanical squeeze pressure in the lending pool today. The ORTEX short score of 62.4 has held in a narrow band for two weeks, confirming the short base is stable rather than building. Options traders are equally unmoved. The put/call ratio is 0.56, a shade below its 20-day average of 0.59 and well within a normal range, with a z-score of -0.48.

The most striking data point this week is how far the analyst community has scrambled to catch up with a stock price the market had already moved. Barclays, on October 7, raised its target from $52 to $110 while keeping an Overweight rating. That single move doubled the target. Leerink Partners and Piper Sandler both raised targets late in September, to $90 and $80 respectively, also from deeply below-market levels. Argus Research initiated at Buy with a $110 target on September 28. Yet the consensus mean sits at just $67.47, well below the $80.66 close, because the revision wave has not yet pulled up the full distribution of estimates. The disconnect is stark. The analyst rec-differentiation factor ranks in the 92nd percentile, and the forward EPS trajectory factor ranks 89th. But value is a genuine sticking point. The PE stands at roughly 1,200 and EV/EBITDA is deeply negative, reflecting a company still loss-making at the operating level. The Benzinga bull case points to consumables growing 5 to 19 times per platform by 2027. The bear case notes revenue contracted in 2024 under double-digit pricing pressure, and the stock has fallen more than 90% from its 2021 peak.

One data point that tempers the bear read on insiders: CEO Serge Saxonov sold roughly 25,000 shares on September 22 across multiple tranches, generating just over $2 million. All transactions were filed under a pre-arranged 10b5-1 trading plan. That classification matters. A planned sale executed on a schedule is routine compensation management, not a discretionary bearish signal. The net 90-day insider figure is negative at around $12.2 million sold, but with the 10b5-1 caveat attached to the visible trades, the read-through is weaker than the headline number suggests.

Institutional ownership tells a more constructive story about long-term conviction. FMR holds 14.2% of shares, T. Rowe Price holds 11.8%, and ARK Investment Management holds 7.7%. T. Rowe added over 9.5 million shares in the most recent quarter, a substantial build. No 13D activist is on the register, and all 13G holders are passive. Stakes are as last disclosed around the 5% threshold; a holder falling below that level may not file again.

The next earnings print is scheduled for November 4, 28 days away. Wikipedia page views for TXG registered a z-score of 2.05 against its own 90-day history in mid-September, suggesting retail attention was running well above normal before the recent pullback. There are no measured leading indicators in the alt data coverage. With the stock now sitting almost exactly at the new Piper Sandler target of $80 and below the Barclays and Argus $110 targets, the November 4 print becomes the next clean test of whether the fundamental story is catching up to the valuation.